Proprioceptive Deficits in Degenerative Cervical Myelopathy
Launched by THE UNIVERSITY OF HONG KONG · Jan 4, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called degenerative cervical myelopathy (DCM), which affects the ability to feel where your body is positioned, leading to problems with balance and movement. The goal of the study is to develop a simple and non-invasive way to assess proprioception—the sense that helps you know where your body is in space—specifically in people over 50 years old. By identifying early signs of DCM, the researchers hope to prevent more serious issues and disabilities that can come from this condition.
To be eligible for the trial, participants must be Chinese, aged 50 or older, and have evidence of DCM, even if they do not currently show symptoms. They should not have other serious conditions that could affect their movement or balance. If you join the study, you can expect to undergo some straightforward physical tests to check your balance and movement abilities. This research is important because it aims to improve early detection and help those at risk maintain a better quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chinese
- • Aged 50 or above
- • With radiological evidence of degenerative cervical myelopathy, both symptomatic and asymptomatic
- • Nurick grade less than 3
- Exclusion Criteria:
- • Non-Chinese ethnicity
- • Aged under 50
- • without any radiological proof of cervical myelopathy
- • Active problems of tuberculosis spine, lumbar spinal diseases, and other problems causing pain or deformities over the limbs that may affect their balance and movement
- • Presents with extra-pyramidal or other disorders involving the cerebellum or frontal lobe of the cerebrum leading to poor balance and gait disturbance
- • Previous spinal operation with residual disturbance in balance or gait
- • Non-communicable patients with insufficient cognitive ability to express their symptoms clearly
- • Non-walker
- • Blind or deaf
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Karlen Ka Pui Law, M. Phil
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials